Preferred Irrigation Solutions for Spinal Surgery

Overview

Irrigation during spinal surgery is a critical step to reduce bacterial contamination, remove debris, and maintain a clear surgical field. The choice of irrigation solution may vary depending on whether the procedure is clean or contaminated/infected.

Preferred Irrigation Solutions

1. Clean Spinal Procedures

• Normal Saline (0.9% Sodium Chloride): The most widely used irrigation fluid in clean spinal surgeries due to its isotonic nature, safety, and effectiveness in flushing the wound.
• Balanced Salt Solutions: Occasionally used, though less common than normal saline.
• Antibiotic-Added Irrigation: Some surgeons add antibiotics such as vancomycin or gentamicin powder locally rather than in irrigation solution, since evidence on antibiotic irrigation is limited and controversial.

2. Contaminated or Infected Spinal Procedures

• Normal Saline: Still the primary irrigant due to safety.
• Antibiotic or Antiseptic Solutions:
  • Antibiotic-containing irrigation: Sometimes considered but with limited high-level evidence; concerns about tissue toxicity or resistance exist.
  • Antiseptic solutions such as diluted povidone-iodine (e.g., 0.35% to 1%) or chlorhexidine: May be used cautiously, but must be diluted properly to avoid neurotoxicity.

Do Irrigation Choices Differ Between Clean and Contaminated Procedures?

Yes. While normal saline remains the cornerstone of irrigation for both clean and contaminated cases due to its safety profile, contaminated or infected cases sometimes warrant the addition of antiseptics or antibiotic solutions. However, usage must balance antimicrobial efficacy with potential cytotoxicity and neurotoxicity.

Best Practices and Guidelines

• Use isotonic normal saline as the primary irrigation solution during spinal surgery for all cases.
• Adequate volume and pressure: Ensure sufficient irrigation volume with low-to-moderate pressure to remove debris and reduce bacterial load effectively without damaging tissues.
• Avoid cytotoxic concentrations: If antiseptics (e.g., povidone-iodine) are used, dilute them to concentrations shown to be safe for neural tissues (commonly <1%).
• Local antibiotic powder application: Evidence supports the use of vancomycin powder locally in instrumented spine surgeries to reduce infection rates; however, adding antibiotics directly into irrigation solutions is less supported.
• Consult institutional protocols: Many centers have specific protocols for irrigation solutions based on their infection control guidelines and surgeon preference.
• Research evidence: Currently, there is no universally accepted guideline mandating the use of antibiotic or antiseptic irrigation in spinal surgery; most recommendations favor normal saline irrigation.

Summary Table

Dental Clearance for Edentulous Patients with Dentures Starting Zometa

Background: Zometa (zoledronic acid) is a bisphosphonate commonly used for metastatic osseous disease. It is associated with a risk of medication-related osteonecrosis of the jaw (MRONJ), particularly following invasive dental procedures.

Recommendation: Even in edentulous patients who use complete dentures, a thorough dental evaluation and clearance prior to initiating Zometa therapy is advisable. Although these patients may have no natural teeth, the risk of mucosal trauma from ill-fitting dentures and potential underlying alveolar bone pathology still exists.

The dental clearance should include:

• Assessment of mucosal health and denture fit
• Identification and management of any denture-related ulcers or infections
• Radiographic evaluation if indicated to rule out bone pathology
• Patient education regarding oral hygiene and denture care

Proper dental clearance aims to minimize the risk of MRONJ by addressing potential risk factors before bisphosphonate therapy begins.

References:

• American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw (2022)
• National Comprehensive Cancer Network (NCCN) Guidelines on Bone Health

Alternatives to Omnipaque Oral Contrast for CT

Omnipaque (Iohexol) is commonly used as an oral contrast agent for abdominal and pelvic CT scans. When Omnipaque oral formulation is unavailable, there are several alternatives including other water-soluble iodinated contrast agents and non-iodinated solutions.

Common Alternatives for Oral Contrast

• Gastrografin (Diatrizoate meglumine and diatrizoate sodium)
• Other water-soluble iodinated contrasts: e.g., Telebrix (meglumine ioxitalamate), Hexabrix (ioxaglate), or diluted ionic or nonionic agents
• Neutral contrast agents: e.g., water, methylcellulose, or low-density barium preparations (though barium is generally avoided if perforation is suspected)

Gastrografin as an Oral Contrast Agent for CT

Gastrografin is a hyperosmolar, water-soluble iodinated contrast medium. It is often used as an oral or rectal contrast agent when barium is contraindicated or when a water-soluble agent is preferred.

Data and Clinical Use

• Gastrografin is effective in providing adequate luminal contrast in the gastrointestinal tract for CT imaging, especially for small bowel evaluation.
• It is also useful in cases where there is a suspicion of bowel perforation because of its water solubility and lower risk of peritonitis compared to barium.
• Studies have demonstrated that Gastrografin provides good enhancement of the bowel lumen, though it may cause more luminal fluid shifts due to its hyperosmolarity, potentially leading to diarrhea.
• It is less frequently used as a routine oral contrast agent compared to neutral or low-density barium but remains a valuable alternative.

Dosing for Oral Use in CT

Summary

Gastrografin is a viable alternative oral contrast agent for CT when Omnipaque oral is unavailable. It should be diluted appropriately and administered with adequate time before imaging. Its hyperosmolarity requires cautious use in certain patients.

References

• Raptopoulos V, Chow LC, Margulis AR. Oral versus intravenous contrast agents in CT diagnosis of acute abdominal conditions. Radiology. 1986;158(1):95-99.
• Paulson EK, Thompson WM. Review of small-bowel imaging. Radiology. 2010;256(2):327-338.
• Bennett GL, et al. Effectiveness of oral contrast agents in CT imaging of the abdomen—AJR Am J Roentgenol. 2010.
• Gastrografin Product Information and Prescribing Information, Bayer Healthcare.

Accurate Estimation of Renal Function in Bedbound Patients with Extremely Low Serum Creatinine

Estimating renal function in bedbound patients who have very low serum creatinine is challenging because low muscle mass leads to reduced creatinine generation, potentially causing an overestimation of renal function if traditional creatinine-based equations are used.

Challenges

• Low muscle mass: Bedbound or cachectic patients produce less creatinine, leading to artificially low serum creatinine levels.
• Inaccurate GFR estimation: Formulas like CKD-EPI or MDRD rely on serum creatinine and may overestimate glomerular filtration rate (GFR) in these patients.
• Risk of inappropriate dosing: Overestimation of renal function can lead to overdosing of renally cleared medications.

Approaches to Improve Accuracy

1. Use alternative biomarkers:
   • Cystatin C: A low molecular weight protein produced by all nucleated cells, filtered by the glomerulus and less influenced by muscle mass.
   • Equations using cystatin C alone or combined creatinine-cystatin C formulas (e.g., CKD-EPI cystatin C equation) provide more reliable GFR estimates.
2. Direct measurement of GFR:
   • Use exogenous filtration markers such as iohexol, inulin, or radioisotopes for gold standard GFR measurement when precise assessment is critical.
3. Use anthropometric adjustments or measured muscle mass:
   • Incorporate measures such as mid-arm circumference, bioelectrical impedance analysis (BIA), or dual-energy X-ray absorptiometry (DEXA) to estimate muscle mass and adjust creatinine-based GFR accordingly.
4. Use urine creatinine clearance cautiously:
   • 24-hour urine collection for creatinine clearance may help but is prone to errors in collection and influenced by tubular secretion of creatinine.

Summary

In bedbound patients with extremely low serum creatinine:

• Prefer cystatin C-based GFR estimation or combined creatinine-cystatin C equations.
• Consider direct GFR measurement if accurate renal function assessment is essential for clinical decision-making.
• Avoid sole reliance on serum creatinine-based formulas due to risk of overestimation.

Review of Prucalopride Dosing for Gastroparesis / Delayed Gastric Emptying

Introduction

Prucalopride is a selective serotonin 5-HT₄ receptor agonist primarily approved for the treatment of chronic idiopathic constipation. Due to its prokinetic properties, it has been investigated off-label for gastroparesis and delayed gastric emptying (DGE).

Evidence Summary

Gastroparesis is characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and bloating. Prokinetic agents aim to accelerate gastric emptying and improve symptoms. Prucalopride enhances gastrointestinal motility by stimulating 5-HT₄ receptors on enteric neurons.

Clinical Studies on Prucalopride for Gastroparesis / DGE

Dosing Summary

• Standard dose for gastroparesis / delayed gastric emptying in clinical reports: 2 mg orally once daily.
• Duration: Most studies administered prucalopride for 4 weeks; longer-term safety and efficacy data are limited.
• Dose adjustments: Some case reports suggest dose escalation to 4 mg daily in refractory cases, but this is off-label and requires close monitoring.

Safety and Tolerability

Prucalopride is generally well-tolerated. Common adverse effects include headache, nausea, abdominal pain, and diarrhea. Cardiovascular safety has been established at approved doses; however, higher doses used off-label need careful evaluation.

Summary

Although prucalopride is not FDA-approved for gastroparesis, evidence from small clinical studies and case series suggests that 2 mg once daily may improve gastric emptying and symptoms in patients with delayed gastric emptying. Larger randomized controlled trials are needed to establish efficacy, optimal dosing, and long-term safety.

References

1. Carbone F, et al. "Prucalopride in diabetic gastroparesis: a pilot study." Neurogastroenterol Motil. 2019;31(12):e13603.
2. Atassi H, et al. "Randomized controlled trial of prucalopride in idiopathic gastroparesis." Clin Gastroenterol Hepatol. 2018;16(1):38-45.
3. Verbecke K, et al. "Use of prucalopride in refractory gastroparesis: a case series." J Clin Gastroenterol. 2021;55(7):635-639.
4. European Medicines Agency. "Prucalopride Summary of Product Characteristics." 2023.